Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

100 results about "Omega-6 fatty acid" patented technology

Omega-6 fatty acids (also referred to as ω-6 fatty acids or n-6 fatty acids) are a family of polyunsaturated fatty acids that have in common a final carbon-carbon double bond in the n-6 position, that is, the sixth bond, counting from the methyl end. Members of the family can have pro-inflammatory or anti-inflammatory effects.

Nutrition bar

A nutrition bar comprising about 10% wt or more of soy and / or rice protein, at least one transition metal or transition metal compound, and about 2% wt or more of a humectant, and wherein the at least one transition metal or transition metal compound is in a substantially water insoluble form at 20° C. or the nutrition bar has an Aw of 0.45 or less or about 1% wt or more of the soy and / or rice protein is in the form of nuggets and the humectant is selected from polyols. The bars have elevated levels of soy and / or rice protein, yet do not suffer unacceptable from a deterioration in taste or other organoleptic properties over time. In other aspects, a nutrition bar or other food which incorporates pro-oxidants and / or polyunsaturated fatty acids or their sources in encapsulated form, especially as microcapsules. The pro-oxidants may be metal salts such as copper, manganese, iron and / or zinc salts. Sources of omega-3 fatty acids include fish oil. Processes for preparing the polyunsaturated fatty acid capsules are also disclosed. The polyunsaturated fatty acid capsules / microcapsules are prepared by forming an emulsion of the unsaturated fatty acid with a carrier, spray drying the emulsion to form a powder and encapsulating powder, especially with a fluid bed. The invention is especially useful for encapsulating polyunsaturated fatty acids, or oil sources thereof, most preferably omega-3 and omega-6 fatty acids, such as arachidonic acid, docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), lineoleic acid, linolenic acid (alpha linolenic acid), and gamma-linolenic acids, fish oil, and oil sources of C18:2 and C18:3 fatty acids such as canola oil, soybean oil or blends thereof.
Owner:SLIM FAST FOODS COMPANY A DIV OF CONOPCO

Fatty Acid Desaturases From Primula

The invention relates generally to methods and compositions concerning desaturase enzymes that modulate the number and location of double bonds in long chain poly-unsaturated fatty acids (LC-PUFA's). In particular, the invention relates to methods and compositions for improving omega-3 fatty acid profiles in plant products and parts using desaturase enzymes and nucleic acids encoding for such enzymes. In particular embodiments, the desaturase enzymes are Primula Δ6-desaturases. Also provided are improved soybean oil compositions having SDA and a beneficial overall content of omega-3 fatty acids relative to omega-6 fatty acids.
Owner:MONSANTO TECH LLC

Glycerophospholipids for the improvement of cognitive functions

Disclosed herein are alternative, enhanced, and cheaper methods of improving cognitive functions in a subject using a lipid composition conjugated with omega-3 and omega-6 fatty acids, with specific amounts and specific conjugation patterns of LA, linolenic acid (alpha-linolenic acid, gamma-linolenic acid) DHA and eicosapentaenoyl (EPA), e.g. utilizing different sources of lipids.Disclosed herein is a lipid preparation, said preparation comprising a phosphatidylserine moiety, and poly-unsaturated fatty acid (PUFA) acyl groups, particularly long-chain poly-unsaturated fatty acid (LC-PUFA) acyl groups such as omega-3 and / or omega-6 acyl groups, wherein said PUFA is covalently bound to said glycerophospholipid. Said lipid preparations are particularly useful in the treatment of mental and cognitive disorders, e.g. ADHD (attention deficit hyperactivity disorder) and Alzheimer's disease.The disclosed preparations present improved bioactivity, and are useful in the treatment of various cognitive and mental conditions and disorders, as well as for maintenance of normal functions of brain-related systems and processes.
Owner:ENZYMOTEC

Lipid system and methods of use

The present invention relates to a lipid system, and methods for using such a lipid system, containing specific relative ratios of omega-3, omega-6, and omega-9 fatty acids. The lipid system may be used independently or as a component of a nutritional product. A lipid system according to the present invention may contain omega-3 fatty acids, omega-6 fatty acids, and omega-9 fatty acids with the ratio of omega-6 fatty acids to omega-3 fatty acids preferably being between 0.25:1 and 3:1, and the ratio of omega-9 fatty acids to omega-3 fatty acids preferably being between 0.4:1 and 3:1. The present invention also relates to methods for administering a lipid system or a nutritional product containing the lipid system to an individual.
Owner:ABBOTT LAB INC

Nutritional preparations

InactiveUS20060217385A1Promote maturityReduce and alleviate fetusBiocideAnimal repellantsPregnancyAdditive ingredient
Compositions and methods for improving the nutritional and physiological status of a woman and her child during all stages of pregnancy are provided herein. This includes pre-conceptional women, pregnant women, and post-natal women (both lactating and non-lactating mothers). The compositions are particularly useful for the neurological, visual, and cognitive development of an embryo, fetus, or infant and the nutritional and physiological well-being of the mother, fetus, and infant. The compositions contain one or more folates, such as a reduced folate and / or folic acid, and one or more essential fatty acids (EFA), such as an omega-3 and / or omega-6 fatty acid. The addition of the essential fatty acid improves upon the folate containing nutritional preparations described in the prior art. The one or more folates and essential fatty acid may be administered together or in separate dosage units. The one or more folates may be selected from folic acid / folate, one or more reduced folates, or a combination of folic acid / folate and one or more reduced folates. The reduced folate is preferably 5-methyltetrahydrofolate, and most preferably 5-methyl-(6S)-tetrahydrofolic acid. The essential fatty acid is preferably an omega-3 fatty acid, and is preferably docosahexenoic acid (DHA) derived from a vegetarian or non-fish source. The compositions may optionally contain other vitamins, minerals, and ingredients, such as, emollient laxatives—all defined herein as “optional or other ingredients”.
Owner:SCIELE PHARMA CAYMAN

Glycerophospholipids containing omega-3 and omega-6 fatty acids and their use in the treatment and improvement of cognitive functions

Disclosed herein is a lipid preparation, said preparation comprising a phosphatidylserine moiety, and poly-unsaturated fatty acid (PUFA) acyl groups, particularly long-chain poly-unsaturated fatty acid (LC-PUFA) acyl groups such as omega-3 and / or omega-6 acyl groups, wherein said PUFA is covalently bound to said glycerophospholipid. Said lipid preparations are particularly useful in the treatment of mental and cognitive disorders, e.g. ADHD (attention deficit hyperactivity disorder) and Alzheimer's disease. The disclosed preparations present improved bioactivity, and are useful in the treatment of various cognitive and mental conditions and disorders, as well as for maintenance of normal functions of brain-related systems and processes.
Owner:ENZYMOTEC

Nutritional preparations

InactiveUS20060217386A1Promote maturityReduce and alleviate fetusBiocideSkeletal disorderPregnancyAdditive ingredient
Compositions and methods for improving the nutritional and physiological status of a woman and her child during all stages of pregnancy are provided herein. This includes pre-conceptional women, pregnant women, and post-natal women (both lactating and non-lactating mothers). The compositions are particularly useful for the neurological, visual, and cognitive development of an embryo, fetus, or infant and the nutritional and physiological well-being of the mother, fetus, and infant. The compositions contain one or more folates, such as a reduced folate and / or folic acid, and one or more essential fatty acids (EFA), such as an omega-3 and / or omega-6 fatty acid. The addition of the essential fatty acid improves upon the folate containing nutritional preparations described in the prior art. The one or more folates and essential fatty acid may be administered together or in separate dosage units. The one or more folates may be selected from folic acid / folate, one or more reduced folates, or a combination of folic acid / folate and one or more reduced folates. The reduced folate is preferably 5-methyltetrahydrofolate, and most preferably 5-methyl-(6S)-tetrahydrofolic acid. The essential fatty acid is preferably an omega-3 fatty acid, and is preferably docosahexenoic acid (DHA) derived from a vegetarian or non-fish source. The compositions may optionally contain other vitamins, minerals, and ingredients, such as, emollient laxatives-all defined herein as “optional or other ingredients”.
Owner:SCIELE PHARMA CAYMAN

Treatment and prevention of liver disease associated with parenteral nutrition (PN)

The present invention is based on the discovery that parenteral nutrition (PN) induced liver disease, e.g. fatty liver disease, can be prevented and even reversed by administration of primarily omega-3-fatty acid with PN rather than the administration of the standard intravenous lipid emulsions that contain primarily plant derived omega-6 fatty acid. Thus, the present invention provides a method for treating or preventing liver disease in a human patient obtaining nutritional support through PN. The method comprises intravenous administration of an effective amount of an omega-3-fatty acid emulsion to the patient, wherein the patient is not administered phytosterols or plant derived fatty acids, e.g. omega-6 fatty acids derived from a plant source, and wherein the administration of the omega-3-fatty acid emulsion to the patient is for a period greater than three weeks. Preferably, the administration is for a period of greater than six weeks. More preferably, the administration is for a period greater than three months.
Owner:CHILDRENS MEDICAL CENT CORP

Nutrition bar or other food product and process of making

A nutrition bar or other food which incorporates pro-oxidants and / or polyunsaturated fatty acids or their sources in encapsulated form, especially as microcapsules. The pro-oxidants may be metal salts such as copper, manganese, iron and / or zinc salts. Sources of omega-3 fatty acids include fish oil. Processes for preparing the polyunsaturated fatty acid capsules are also disclosed. The polyunsaturated fatty acid capsules / microcapsules are prepared by forming an emulsion of the unsaturated fatty acid with a carrier, spray drying the emulsion to form a powder and encapsulating powder, especially with a fluid bed. The invention is especially useful for encapsulating polyunsaturated fatty acids, or oil sources thereof, most preferably omega-3 and omega-6 fatty acids, such as arachidonic acid, docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), lineoleic acid, linolenic acid (alpha linolenic acid), and gamma-linolenic acids, fish oil, and oil sources of C18:2 and C18:3 fatty acids such as canola oil, soybean oil or blends thereof.
Owner:SLIM FAST FOODS

Dietary supplement for enhancing animal health

InactiveUS20130216521A1Decrease clinical sign of diseaseShorten courseBiocidePeptide/protein ingredientsAntioxidantDietary supplement
A dietary supplement system including three general components is provided. The first component is the fatty acid component and this includes sunflower seeds (containing omega 6 fatty acids), flax seed (containing omega 3 fatty acids) and powdered oils (containing omega 3 or omega 6 fatty acids and generally produced from sunflower oils). The weight ratio of omega 6 fatty acids to omega 3 fatty acids is 10:1 to 1:1, with 10:1 to 5:1 being preferred for normal animals and 2:1 to 1:1 being preferred for animals which have fatty acid responsive conditions. The second component is the GI component, which is used for facilitating animal gut health. This component includes prebiotics, probiotics and immunoglobulin (typically from albumin concentrate). The third component is the breed specific component and can include vitamins, minerals, additional fatty acids, antioxidants, amino acids, palatants, and nutraceutical additives.
Owner:HARTZ MOUNTAIN

Treatment and Prevention of Liver Disease Associated with Parenteral Nutrition (PN)

The present invention is based on the discovery that parenteral nutrition (PN) induced liver disease, e.g. fatty liver disease, can be prevented and even reversed by administration of primarily omega-3-fatty acid with PN rather than the administration of the standard intravenous lipid emulsions that contain primarily plant derived omega-6 fatty acid. Thus, the present invention provides a method for treating or preventing liver disease in a human patient obtaining nutritional support through PN. The method comprises intravenous administration of an effective amount of an omega-3-fatty acid emulsion to the patient, wherein the patient is not administered phytosterols or plant derived fatty acids, e.g. omega-6 fatty acids derived from a plant source, and wherein the administration of the omega-3-fatty acid emulsion to the patient is for a period greater than three weeks. Preferably, the administration is for a period of greater than six weeks. More preferably, the administration is for a period greater than three months.
Owner:CHILDRENS MEDICAL CENT CORP

Lipid System and Methods of Use

The present invention relates to a lipid system, and methods for using such a lipid system, containing specific relative ratios of omega-3, omega-6, and omega-9 fatty acids. The lipid system may be used independently or as a component of a nutritional product. A lipid system according to the present invention may contain omega-3 fatty acids, omega-6 fatty acids, and omega-9 fatty acids with the ratio of omegas-6 fatty acids to omega-3 fatty acids preferably being between 0.25:1 and 3:1, and the ratio of omega-9 fatty acids to omega-3 fatty acids preferably being between 0.4:1 and 3:1. The present invention also relates to methods for administering a lipid system or a nutritional product containing the lipid system to an individual.
Owner:ABBOTT LAB INC

Lipids containing omega-3 and omega-6 fatty acids

A lipid preparation including a glycerophospholipid or salt, conjugate and derivatives thereof, particularly phosphatidylserine (PS), phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidyl-inositol (PI), phosphatidylglycerol (PG) and phosphatidic acid (PA), and poly-unsaturated fatty acid (PUFA) acyl groups, particularly long-chain poly-unsaturated fatty acid (LC-PUFA) acyl groups such as omega-3 and / or omega-6 acyl groups, wherein said PUFA is covalently bound to said glycerophospholipid. The preparation possesses an improved bioactivity, and is useful in the treatment of various cognitive and mental conditions and disorders and for maintenance of normal functions of brain-related systems and processes.
Owner:ENZYMOTEC

Compositions, Methods, and Kits for Polyunsaturated Fatty Acids from Microalgae

InactiveUS20130323801A1Promote human well-beingBacteriaFatty acid esterificationBiotechnologyDisease
The present invention provides compositions, methods, and kits comprising PUFAs produced by microalgae, in particular omega-3 and / or omega-6 fatty acids produced by members of the genus Rhodomonas, in particular Rhodomonas salina and / or genetically engineered bacteria or co-cultures of microalgae and bacteria. The invention also provides compositions, methods, and kits comprising the PUFAs for the prophylactic and / or therapeutic treatment of a disease or condition, in particular a cardiovascular and / or inflammatory disease or condition.
Owner:WAKE FOREST UNIV

Health-care corn oil containing peony seed oil and preparing method thereof

The invention discloses health-care corn oil containing peony seed oil and a preparing method thereof. The health-care corn oil adopts edible vegetable oil rich in omega-3 and omega-6 polyunsaturated fatty acids as a raw material and is edible oil which is formed by mixing corn oil and the peony seed oil. The health-care corn oil containing the peony seed oil, disclosed by the invention, has the advantages of solving the problem that the proportions of fatty acids in the conventional corn oil are out of balance and in particular, the proportions of the omega-3 and omega-6 fatty acids are out of balance, having a simple formula, enabling the preparation of the corn oil to be more reasonable and being the novel health-care corn oil with more comprehensive nutrition, good mouth feeling and better health-care performance.
Owner:SHANDONG SANXING CORN IND SCI CO LTD

Infant formula with high sn-2 palmitate and oligofructose

An infant formula having a relatively high content of triglycerides having palmitic acid in the sn-2 position. The formula may include oligofructose. The formula may also include at least one omega 6 fatty acid and at least one omega 3 fatty acid. The formula may also have a relatively low protein content and an alpha-lactalbumin content similar to human milk The invention also includes a method for improving the stool consistency, increasing bifidobacteria in the colon, reducing potentially pathogenic bacteria in the colon and reducing calcium soaps in the stool of a formula-fed infant.
Owner:NESTEC SA

Fatty acid desaturases from primula

The invention relates generally to methods and compositions concerning desaturase enzymes that modulate the number and location of double bonds in long chain poly-unsaturated fatty acids (LC-PUFA's). In particular, the invention relates to methods and compositions for improving omega-3 fatty acid profiles in plant products and parts using desaturase enzymes and nucleic acids encoding for such enzymes. In particular embodiments, the desaturase enzymes are Primula Δ6-desaturases. Also provided are improved soybean oil compositions having SDA and a beneficial overall content of omega-3 fatty acids relative to omega-6 fatty acids.
Owner:MONSANTO TECH LLC

Glycerophospholipids containing omega-3 and omega-6 fatty acids

Disclosed is a lipid preparation comprising a glycerophospholipid or salt, conjugate and derivatives thereof, particularly phosphatidylserine (PS), phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidyl-inositol (PI), phosphatidylglycerol (PG) and phosphatidic acid (PA), and poly-unsaturated fatty acid (PUFA) acyl groups, particularly long-chain poly-unsaturated fatty acid (LC-PUFA) acyl groups such as omega-3 and / or omega-6 acyl groups, wherein said PUFA is covalently bound to said glycerophospholipid. The disclosed preparations possess an improved bioactivity, and are useful in the treatment of various cognitive and mental conditions and disorders and for maintenance of normal functions of brain-related systems and processes, for example ADHD.
Owner:ENZYMOTEC

Compositions and methods for the treatment of gastrointestinal conditions

InactiveUS20080118441A1Few and no side effectSuitable for useBiocideAerosol deliveryIntestinal structureDiverticulitis
Gastrointestinal conditions, such as gastroesophageal reflux disease, heartburn, acid indigestion, constipation, irritable bowel syndrome, stomach and intestinal ulcers, gastrointestinal tract inflammation, thrush, diverticulitis, ulcerative colitis, Crohn's disease, diarrhea and cancers of the esophagus, pancreas, stomach, intestines and colon, may be treated or prevented by administration of compositions containing a therapeutically effective amount of a fatty acid and a therapeutically effective amount of mucilaginous fiber. Fatty acids suitable for use in the compositions include omega-3 fatty acids, omega-6 fatty acids and / or omega-9 fatty acids.
Owner:WASHINGTON JOSEPH A

Nutrition-balanced edible blend oil

The invention discloses nutrition-balanced edible blend oil. The blend oil is prepared from the following raw material oil in parts by weight: 4 parts of flaxseed oil, 18 to 28 parts of corn oil, 8 to 15 parts of hemp oil, 8 to 12 parts of rice oil and 10 to 20 parts of tea oil; moreover, the various raw oil is weighed according to a weight ratio 1:(3.5 to 4.5):(4.5 to 5.5) of omega-3 fatty acid to omega-6 fatty acid to omega-9 fatty acid. The blend oil is coordinated in a proportion among the fatty acids, is reasonable in formula, is balanced in nutrition, has the effects of lowering blood pressure, lowering fat, lowering the incidence probability of coronary heart disease, preventing senile dementia and the like, and is very suitable for middle aged and elderly people to eat; by adopting the balanced-nutrition edible blend oil, intake of fatty acids necessary for sustaining life can be ensured.
Owner:广西茶仔龙科技股份有限公司

Glycerophospholipids containing omega-3 and omega-6 fatty acids and their use in the treatment and improvement of cognitive functions

Disclosed herein is a lipid preparation, said preparation comprising a phosphatidylserine moiety, and poly-unsaturated fatty acid (PUFA) acyl groups, particularly long-chain poly-unsaturated fatty acid (LC-PUFA) acyl groups such as omega-3 and / or omega-6 acyl groups, wherein said PUFA is covalently bound to said glycerophospholipid. Said lipid preparations are particularly useful in the treatment of mental and cognitive disorders, e.g. ADHD (attention deficit hyperactivity disorder) and Alzheimer's disease.The disclosed preparations present improved bioactivity, and are useful in the treatment of various cognitive and mental conditions and disorders, as well as for maintenance of normal functions of brain-related systems and processes.
Owner:ENZYMOTEC

Fatty acid desaturases from primula

The invention relates generally to methods and compositions concerning desaturase enzymes that modulate the number and location of double bonds in long chain poly-unsaturated fatty acids (LC-PUFA's). In particular, the invention relates to methods and compositions for improving omega-3 fatty acid profiles in plant products and parts using desaturase enzymes and nucleic acids encoding for such enzymes. In particular embodiments, the desaturase enzymes are Primula Δ6-desaturases. Also provided are improved soybean oil compositions having SDA and a beneficial overall content of omega-3 fatty acids relative to omega-6 fatty acids.
Owner:MONSANTO TECH LLC

Preparation and Use of High Omega-3 and Omega-6 Feed

A method of preparing an animal feed component by mixing at least one ground pulse product with whole or intact oilseeds is herein described. The mixture is subjected to heat of between 230 F to 350 F and pressure of between 200 to 400 psi during an extrusion process. Also described is the use of the feed component in the production of animal products having increased levels of omega-3 and omega-6 fatty acids.
Owner:WIENS TIM

Novel method for the production of polyunsaturated fatty acids

The present invention relates to an improved process for the specific production of poly-unsaturated omega-3 and omega-6 fatty acids and a process for the production of triglycerides having an increased content of unsaturated fatty acids, in particular omega-3 and omega-6 fatty acids having at least two double bonds and a 20 or 22 carbon atom chain length. The invention relates to the produc-tion of a transgenic organism, preferably a transgenic plant or a transgenic microorganism, hav-ing an increased content of fatty acids, oils or lipids containing C20- or C22- fatty acids with a delta-5, 7, 8, 10 double bond, respectively due to the expression of a delta-8-desaturase and a delta-9- elon-gase from organisms such as plants preferably Algae like Isochrysis galbana or Euglena gracilis. In addition the invention relates to a process for the production of poly unsaturated fatty acids such as Eicosapentaenoic, Arachidonic, Docosapentaenoic or Docosahexaenoic acid through the co- expression of a delta -8-desaturase, a delta-9-elongase and a delta-5 desaturase in organisms such as microorganisms or plants.The invention additionally relates to the use of specific nucleic acid sequences encoding for the aforementioned proteins with delta-8-desaturase-, delta-9-elongase- or delta-5-desaturase-activity, nucleic acid constructs, vectors and organisms containing said nucleic acid sequences. The invention further relates to unsaturated fatty acids and triglycerides having an increased content of at least 1 % by weight of unsaturated fatty acids and use thereof.
Owner:UNIV OF BRISTOL

Composition and method for improving gastrointestinal health of equine

A composition to moderate excessive and potentially harmful gastric acid levels in the gastrointestinal tract of horses is disclosed. The composition includes calcium oxide and / or calcium hydroxide, which may be in combination with various buffers and other ingredients such as sodium bicarbonate, sodium bentonite, sodium sesquicarbonate, calcium carbonate, magnesium oxide, omega-3 and omega-6 fatty acid sources, simple carbohydrates, and / or probiotics. A method of administering the composition is also disclosed.
Owner:PHOTO FINISH SUPPLEMENTS

Beverage

The present invention provides a beverage, comprising: 5-35% weight / volume fat and / or oil, wherein the fat / oil comprises vegetable oils, and comprises a maximum of 30% weight / volume saturated fatty acids and minimum 20% weight / volume unsaturated fatty acids, said unsaturated fatty acids comprising omega-3-fatty acids and omega-6-fatty acids, and the weight ratio of said omega-6 fatty acids to said omega-3 fatty acids is no greater than 4:1; a maximum of 2.5% weight / volume of carbohydrates; and lactic acid; wherein the content of fat and / or oil is higher than the carbohydrate content by weight. The beverage is especially suitable for patients suffering from inflammatory diseases (Ulcerative Colitis, Rheuma, Multiple Sclerosis), from diabetes and associated chronic diabetes complications (retinopahty, neuropathy, nephropathy, micro- and macrovascular damages e.g. blood vessel damages, myocardial infarction), from neurodegenerative diseases (Alzheimer's, Wernicke-Korsakoff syndrome), and from cancer.
Owner:TAVARTIS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products